Share
The pharma industry briefing
The latest news, approvals and clinical trials you need to know about this month
Data:
News in Numbers
69%
The approximate proportion of CMO high-containment facilities in Europe that can be found in the 5EU and Switzerland
98%
The Philippines Department of Health has recorded that from January to 20 July there was a 98% increase in dengue fever cases on the same period last year
2
The number of Ebola drugs that have shown promise in clinical trials amid the ongoing outbreak in the Democratic Republic of Congo
6
The number of new drugs in the pipeline that address the need for personalised prostate cancer treatments
$20m
The up-front price that Pharming has agreed to pay to acquire leniolisib, a late-stage pipeline drug aimed at a rare disease of the immune system, from Novartis
Data:
News In Numbers
98%
The Philippines Department of Health has recorded that from January to 20 July there was a 98% increase in dengue fever cases on the same period last year
2
The number of Ebola drugs that have shown promise in clinical trials amid the ongoing outbreak in the Democratic Republic of Congo
69%
The approximate proportion of CMO high-containment facilities in Europe that can be found in the 5EU and Switzerland
6
The number of new drugs in the pipeline that address the need for personalised prostate cancer treatments
$20m
The up-front price that Pharming has agreed to pay to acquire leniolisib, a late-stage pipeline drug aimed at a rare disease of the immune system, from Novartis
Novartis benefits from faster China drug approvals
Novartis, the Swiss pharmaceutical company, plans to submit 50 new drug applications in China over the next few years, as it projects faster Chinese drug approvals which could see the country overtake Europe to become its second-largest market.
Source: The Financial Times
China to set up inspection teams to ensure drug safety
China will set up specialized inspection teams of pharmaceutical professionals at central and provincial levels to tighten the supervision and regulation of drug safety, including medical equipment and cosmetics.
Source: Xinhua
Drugmakers named for breaching UK code
Daiichi-Sankyo, GW Pharmaceuticals, Bayer, Proveca and Otsuka will be named in advertisements following breaches of the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry.
Source: The Pharma Letter
AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatment
AstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this time in first-line treatment of advanced ovarian cancer.
Source: Pharmaphorum
Allergan's bid to shield Botox manufacturing secrets from competitors backfires
A US International Trade Commission judge has ordered Allergan to turn over details of its Botox manufacturing to Evolus and South Korea-based Daewoong, the makers of rival Jeuveau, as part of an investigation the Irish drugmaker requested in February.
Source: Fierce Pharma
Approvals
AR-501
Aridis Pharmaceuticals has been granted orphan drug designation for AR-501, its inhaled formulation of gallium citrate for treatment of lung infection in patients with cystic fibrosis.
Source: Cision
Vitrakvi (larotrectinib)
The EMA has announced its approval for marketing authorisation in the EU for Vitrakvi, used to treat solid tumours with a specific gene mutation.
Source: European Pharmaceutical Review
TURALIO (pexidartinib)
The FDA has approved Daiichi Sankyo’s TURALIO for the treatment of select patients with symptomatic tenosynovial giant cell tumour.
Source: Daiichi-Sankyo
Lynparza (olaparib)
A “game-changing” drug for women living with ovarian cancer has received approval as a first stage treatment on the NHS.
Source: Independent
Go to top
Go to top
Share this article
